The University of Chicago Header Logo
Last Name


Michael H. Davidson to Haloperidol

This is a "connection" page, showing publications Michael H. Davidson has written about Haloperidol.

Connection Strength
  1. Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006 Jul; 189:31-5.
    View in: PubMed
    Score: 0.315
  2. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005 Oct; 162(10):1888-95.
    View in: PubMed
    Score: 0.299
  3. Rabinowitz J, Davidson M. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res. 2001 May 30; 50(1-2):89-93.
    View in: PubMed
    Score: 0.222
  4. Rabinowitz J, Hornik T, Davidson M. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry. 2001 May; 62(5):343-6.
    View in: PubMed
    Score: 0.220
  5. Davidson M, Kahn RS, Knott P, Kaminsky R, Cooper M, DuMont K, Apter S, Davis KL. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry. 1991 Oct; 48(10):910-3.
    View in: PubMed
    Score: 0.113
  6. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005 May; 162(5):947-53.
    View in: PubMed
    Score: 0.073
  7. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry. 1993 Aug; 50(8):599-605.
    View in: PubMed
    Score: 0.032
  8. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C. Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology (Berl). 1993; 112(1 Suppl):S90-4.
    View in: PubMed
    Score: 0.031
  9. Harvey PD, Putnam KM, Davidson M, Kahn RS, Powchik P, McQueeney R, Keefe RS, Davis KL. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991 Sep; 38(3):285-92.
    View in: PubMed
    Score: 0.028
  10. Earle-Boyer EA, Serper MR, Davidson M, Harvey PD. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Res. 1991 Apr; 37(1):47-56.
    View in: PubMed
    Score: 0.027
  11. Harvey PD, Davidson M, White L, Keefe RS, Hirschowitz J, Mohs RC, Davis KL. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry. 1996 Oct 15; 40(8):755-60.
    View in: PubMed
    Score: 0.010
  12. Harvey PD, Davidson M, Powchik P, Schmeidler J, McQueeney R, Kaminsky R, Davis KL. Time course and clinical predictors of treatment response in schizophrenia. Schizophr Res. 1991 Sep; 5(2):161-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.